Intra-Cellular Therapies, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • ITCI
  • 1d-1.70%
  • 1w-5.63%
  • 1m-0.03%
  • 1y7.56%
ATH
  • ATH Price$75.65
  • ATH Date2024-02-16
  • % since ATH-14.40%
  • % to ATH16.82%
ATL
  • ATL Price$7.26
  • ATL Date2019-10-01
  • % from ATL792.01%
  • Last Low Price$64.37
  • Last Low Date2024-03-12
  • % From Last Low0.61%
IPO
  • IPO Price$10.00
  • % Current ROI USD647.60%
  • ATH Price$75.65
  • % ROI ATH 104,201.10%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="ITCI"]

Key Data [addtoany]

Current price $64.76
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Today's High/Low $66.05/$64.155
Volume 503,310.00
Previous Close $65.88
52 Week High/Low $76.11/$45.5
Market Cap 6,269,234,688.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $1.15
Annualized Dividend $0
$64.76
[addtoany]

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States.
The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders.
In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson’s disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity